MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

35.92 -0.69

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.95

Max

36.9

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 51M
Verkäufe	39M 239M
KGV Branchendurchschnitt	11.426 89.037
EPS	1.08
Gewinnspanne	21.242
Angestellte	268
EBITDA	14M 73M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+20.79% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	399M 2.1B
Vorheriger Eröffnungskurs	36.61
Vorheriger Schlusskurs	35.92

Nachrichtenstimmung

By Acuity

58%

42%

310 / 361 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Jan. 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20. Jan. 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20. Jan. 2026, 23:41 UTC

Ergebnisse

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20. Jan. 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20. Jan. 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Jan. 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20. Jan. 2026, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20. Jan. 2026, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20. Jan. 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20. Jan. 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20. Jan. 2026, 22:27 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20. Jan. 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20. Jan. 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20. Jan. 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20. Jan. 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20. Jan. 2026, 22:18 UTC

Ergebnisse

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20. Jan. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20. Jan. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20. Jan. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20. Jan. 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20. Jan. 2026, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20. Jan. 2026, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20. Jan. 2026, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20. Jan. 2026, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20. Jan. 2026, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20. Jan. 2026, 22:06 UTC

Ergebnisse

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20. Jan. 2026, 22:00 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

ESG Roundup: Market Talk

20. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

20.79% Vorteil

12-Monats-Prognose

Durchschnitt 43.75 USD 20.79%

Hoch 55 USD

Tief 32 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

310 / 361 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.